Black Diamond Therapeutics, Inc. SEC filings BDTX

Black Diamond Therapeutics, Inc. has 485 filings in SEC EDGAR's recent list, going back to Mar 28, 2017. Its latest annual report, Form ARS, was filed on Apr 29, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 5, 2026 (results of operations). The company's fiscal year ends on December 31.

Form Description Filed Period
ARS Annual report to shareholders Apr 29, 2026 Dec 31, 2025
10-K Annual report Mar 16, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 18, 2025 Dec 31, 2024
10-K Annual report Mar 6, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 24, 2024 Dec 31, 2023
10-K Annual report Mar 12, 2024 Dec 31, 2023
ARS Annual report to shareholders Apr 4, 2023 Dec 31, 2022
10-K Annual report Mar 9, 2023 Dec 31, 2022
10-K Annual report Mar 17, 2022 Dec 31, 2021
10-K Annual report Mar 25, 2021 Dec 31, 2020
10-K Annual report Mar 24, 2020 Dec 31, 2019

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
BDTX (Nasdaq)
Fiscal year ends
December 31
Headquarters
Cambridge, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1701541
Former names
Aset Therapeutics, Inc. (until Jan 4, 2018)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.